Mike Mensinger Sells 2,650 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 2,650 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total value of $58,300.00. Following the sale, the insider directly owned 177,390 shares of the company’s stock, valued at $3,902,580. This represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mike Mensinger also recently made the following trade(s):

• On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total value of $83,606.25.

Beta Bionics Trading Down 3.4%

Shares of NASDAQ:BBNX traded down $0.75 during mid-day trading on Thursday, hitting $21.43. 3,089,176 shares of the company traded hands, compared to its average volume of 1,193,079. The stock has a market cap of $964.14 million, a P/E ratio of -12.99 and a beta of 3.37. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The stock has a 50-day moving average price of $17.46 and a two-hundred day moving average price of $13.93.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. As a group, analysts expect that Beta Bionics, Inc. will post -2.05 earnings per share for the current year.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The U.S. FDA cleared Beta Bionics’ Mint patch pump, expanding the company’s diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, creating a potential additional growth driver. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Analysts and market coverage have highlighted the Mint clearance as a step toward a broader, multi-product growth strategy. Recent earnings-estimate trends and a price-target increase from Bank of America also supported buying interest. Beta Bionics Shares Rise After BofA Price-Target Boost
• Positive Sentiment: Beta Bionics priced a public offering expected to raise approximately $150 million. The proceeds could fund Mint commercialization, manufacturing expansion, research and development, and working capital, improving financial flexibility. Beta Bionics Announces Pricing of Public Offering
• Neutral Sentiment: The offering includes 7.65 million common shares and pre-funded warrants for approximately 1.04 million additional shares, with a potential underwriters’ option for 1.30 million more shares. The capital raise strengthens the balance sheet but increases the potential share count.
• Negative Sentiment: Multiple law firms are publicizing a securities class action against Beta Bionics. The litigation alleges that management understated the significance of FDA Form 483 findings, a subsequent warning letter, quality-management issues, and unreported customer complaints. Investors have until November 3, 2026, to seek lead-plaintiff status; the allegations have not been proven. BBNX Shareholder Alert
• Negative Sentiment: Beta Bionics’ updated 2026 revenue outlook of $121 million to $126 million is below the roughly $133.9 million consensus estimate, raising concerns about near-term execution and commercialization. The equity offering may also weigh on the stock through dilution.

Hedge Funds Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Beta Bionics during the second quarter valued at about $52,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Beta Bionics in the fourth quarter worth about $40,437,000. Eversept Partners LP boosted its stake in Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares during the last quarter. 12 West Capital Management LP bought a new position in shares of Beta Bionics during the 4th quarter valued at approximately $17,520,000. Finally, Bruce & Co. Inc. purchased a new stake in shares of Beta Bionics during the 1st quarter worth approximately $5,518,000.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. William Blair started coverage on shares of Beta Bionics in a report on Friday, August 21st. They issued a “market perform” rating for the company. The Goldman Sachs Group upped their price objective on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Robert W. Baird increased their price objective on shares of Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday. Truist Financial reissued a “buy” rating and set a $23.00 target price (up from $22.00) on shares of Beta Bionics in a research report on Tuesday. Finally, Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.90.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.